Nykamp, Madeline J.;
Zorumski, Charles F.;
Reiersen, Angela M.;
Nicol, Ginger E.;
Cirrito, John;
Lenze, Eric J.
Opportunities for Drug Repurposing of Serotonin Reuptake Inhibitors:
Potential Uses in Inflammation, Infection, Cancer, Neuroprotection, and
Alzheimer’s Disease Prevention
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
Opportunities for Drug Repurposing of Serotonin Reuptake Inhibitors:
Potential Uses in Inflammation, Infection, Cancer, Neuroprotection, and
Alzheimer’s Disease Prevention
Beteiligte:
Nykamp, Madeline J.;
Zorumski, Charles F.;
Reiersen, Angela M.;
Nicol, Ginger E.;
Cirrito, John;
Lenze, Eric J.
Erschienen:
Georg Thieme Verlag KG, 2022
Erschienen in:Pharmacopsychiatry
Sprache:
Englisch
DOI:
10.1055/a-1686-9620
ISSN:
0176-3679;
1439-0795
Entstehung:
Anmerkungen:
Beschreibung:
<jats:title>Abstract</jats:title><jats:p>Serotonin reuptake inhibitors (SRIs) are safe and widely used for a variety of
indications including depressive disorders, anxiety, and chronic pain. Besides
inhibiting the serotonin transporter, these medications have broad-spectrum
properties in many systems. Their roles have been studied in cancer,
Alzheimer’s disease, and infectious processes. The COVID-19 pandemic
highlighted the importance of drug repurposing of medications already in use. We
conducted a narrative review of current evidence and ongoing research on drug
repurposing of SRIs, with a focus on immunomodulatory, antiproliferative, and
neuroprotective activity. SRIs may have clinical use as repurposed agents for a
wide variety of conditions including but not limited to COVID-19,
Alzheimer’s disease, and neoplastic processes. Further research,
particularly randomized controlled trials, will be necessary to confirm the
utility of SRIs for new indications.</jats:p>